All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · newborns with late‐onset sepsis
It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether ampicillin plus gentamicin changes all‐cause mortality maximum compared with penicillin plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin changes all‐cause mortality maximum compared with ampicillin plus amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether piperacillin plus tazobactam changes all‐cause mortality maximum compared with amikacin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates with early‐onset sepsis
It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with piperacillin plus gentamicin (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes all‐cause mortality Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
All‐cause mortality maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
1 finding from 1 review
Intervention not reported
Infection‐related mortality · cancer patients receiving myelotoxic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Meningitis‐related mortality · patients with a recent BSF independent of the presence or severity of CSF leakage
The intervention showed no clear difference in meningitis‐related mortality (moderate certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
All‐cause mortality at day 28 · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Intervention not reported
Mortality Clinical assessment · newborn infants who require a central venous catheter
It is very uncertain whether the intervention changes mortality Clinical assessment (very low certainty).
1 finding from 1 review
Intervention not reported
Secondary ‐ All‐cause mortality · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Secondary ‐ All cause mortality · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found